Abstract B155: IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumors

作者
Eric Haines,Rachel Catterall,Victor De Jesus,Bin Li,Sarah R. Wessel,Jill Cavanaugh,Michael Burke,Joseph Manna,Okzana Zavidij,Ao Yang,Lan Xu,Sergio Santillana,Jeffrey Ecsedy,X. Michelle Zhang,Sabine K. Ruppel
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): B155-B155
标识
DOI:10.1158/1535-7163.targ-23-b155
摘要

Abstract Alterations in the RAS/RAF/MEK/ERK pathway are the most common drivers of oncogenesis. Although MEK is a clinically validated cancer target and several MEK inhibitors have been approved by the FDA, their clinical utility has been limited to BRAF V600 mutant cancers and NF1 mutant neurofibromas. We developed IK-595, a potent inhibitor of the MEK-RAF complex, to overcome the limitations of available MEK inhibitors. IK-595 traps MEK in an inactive complex with all RAF isoforms and blocks RAF-dependent MEK phosphorylation, thereby alleviating CRAF-mediated MEK reactivation that hinders the efficacy of approved MEK inhibitors in RAS/RAF-driven tumors. We demonstrate that IK-595 leads to potent and prolonged inhibition of MEK and ERK1/2 phosphorylation, in KRAS-mutant cancer and NRAS-mutant melanoma models. In addition to trapping all three RAF isoforms, IK-595 stabilizes the interaction of MEK with BRAF Class I, II, and III mutant proteins. This delays the onset of known resistance mechanisms to other MAPK pathway targeting agents, such as CRAF-mediated pathway reactivation and receptor tyrosine kinase upregulation and/or activation. Importantly, IK-595 has a much slower off-rate binding to MEK and retains CRAF longer in an inactive complex with MEK than other MEK/RAF inhibitors allowing for more prolonged target engagement and durable pathway inhibition in RAS/RAF mutant cancer cells. Moreover, CRAF-ARAF heterodimerization, which is detected in type II pan-RAF inhibitor-treated KRAS mutant cells as an established resistance mechanism, is not observed upon IK-595 treatment. IK-595 exhibits potent signal agent activity across a wide range of cancer models harboring various RAS/RAF alterations, including lung, pancreatic, colorectal cancer (CRC), melanoma, AML, and others. Strong synergy with inhibitors targeting multiple key mechanisms, both within the RAS/MAPK pathway and across parallel survival pathways, has also been observed in multiple models. Key to the design of IK-595 is its PK profile that enables transient high plasma drug exposure and flexible dosing schedules. Intermittent dosing of IK-595 every other day (QOD) or every three days (Q3D) in KRAS mutant mouse tumor models shows similar efficacy and improved tolerability compared to daily dosing (QD), affording a larger therapeutic window. Preclinical pharmacology studies provide clear guidance to the clinical development plan of IK-595, where flexible dosing schedules and multiple expansion cohorts in RAS/RAF altered patient populations will be explored. IK-595 is a novel MEK-RAF complex inhibitor that prolongs pathway inhibition, minimizing the potential for resistance, while providing an optimal therapeutic window for patients with RAS/RAF-driven cancer. Citation Format: Eric Haines, Rachel Catterall, Victor De Jesus, Bin Li, Sarah R Wessel, Jill Cavanaugh, Michael Burke, Joseph D Manna, Okzana Zavidij, Ao Yang, Lan Xu, Sergio Santillana, Jeffrey Ecsedy, X. Michelle Zhang, Sabine K Ruppel. IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B155.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威威发布了新的文献求助10
刚刚
JamesPei的应助被xxh采纳,获得10
刚刚
远了个方发布了新的文献求助10
1秒前
Akim的应助被多情的仰采纳,获得10
1秒前
远了个方发布了新的文献求助10
1秒前
远了个方发布了新的文献求助10
1秒前
远了个方发布了新的文献求助10
1秒前
远了个方发布了新的文献求助10
1秒前
2秒前
Knee发布了新的文献求助10
2秒前
vv完成签到 ,获得积分10
2秒前
红叶完成签到,获得积分10
2秒前
所所的应助被Jio-PPx采纳,获得10
3秒前
3秒前
3秒前
JamesPei的应助被清河响啊啊采纳,获得10
3秒前
可爱的函函的应助被小生不才采纳,获得10
3秒前
4秒前
晨gegeai发布了新的文献求助10
5秒前
研友_VZG7GZ的应助被盒子采纳,获得10
5秒前
科研通AI65的应助被好人采纳,获得10
5秒前
嘎嘎嘎完成签到,获得积分10
6秒前
无极微光的应助被ESTHERDY采纳,获得20
6秒前
shadow发布了新的文献求助10
6秒前
6秒前
搜集达人的应助被Joany采纳,获得10
7秒前
maomao发布了新的文献求助10
8秒前
cY完成签到,获得积分10
8秒前
8秒前
Jasper的应助被友好的诗筠采纳,获得10
10秒前
麦粑块发布了新的文献求助10
10秒前
11秒前
11秒前
zzk发布了新的文献求助10
13秒前
holoka完成签到,获得积分20
13秒前
取名叫做利完成签到 ,获得积分10
13秒前
jiangxiang完成签到,获得积分20
13秒前
14秒前
Reese发布了新的文献求助10
14秒前
慕青的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239